2016-12-05

[#DIV28SUPER] LEAD Training Program


Training Opportunity for Underrepresented Early-Career Addictions Researchers!

We are happy to announce that the Learning for Early Careers in Addiction and Diversity (LEAD) Program is recruiting its new cohort!

The LEAD Program is an NIH-sponsored R25 training program that uses the NIDA CTN as a platform for providing research training to early-career investigators from underrepresented racial/ethnic minority groups conducting research in the substance use disorder (SUD) treatment and services field. This 2-year training program is based at the University of California, San Francisco (UCSF). Program scholars will spend 4 weeks at UCSF each summer and will develop and execute a pilot study at their home institution throughout the academic year. The program provides travel and housing funds as well as up to $25,000 to conduct the pilot study, which will serve as foundational data to support the submission of an R or K application. The program is directed by Carmen Masson, PhD, and James Sorensen, PhD, at UCSF.

 

The program recruitment flyer containing further information on eligibility criteria and selection process is attached. The deadline for applications is January 31, 2017. For any questions or to nominate a qualified candidate, please contact Rebecca Cook at rebecca.cook@ucsf.edu. Additional information can be found at http://psych.ucsf.edu/lead/.

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2016-12-02

[#DIV28SUPER] Call for Nominations - Division 28 Awards

Dear Colleagues:  

Happy Holidays to everyone!

I am writing to encourage you to submit nomination materials for APA Division 28 Awards for the 2017 APA meeting in Washington, D.C.  Attached you will find the official call for nominations with the detailed instructions for each of the three awards:  Med Associates Brady-Schuster Award, Young Psychopharmacologist Award and Outstanding Dissertation Award.  These awards are an excellent way to recognize your outstanding colleagues in science- both the young and more seasoned!  The Awards Committee looks forward to seeing this year’s nominees.  The deadline for materials is January 15, 2017.  

The deadline is about 6 weeks away!  Don’t delay!

 

Regards,

 

Cathy Stanger

 

 

Catherine Stanger, Ph.D.

Associate Professor

Department of Psychiatry

Geisel School of Medicine at Dartmouth

46 Centerra Parkway

Suite 300, HB 7255

Lebanon, NH 03766

Catherine.stanger@dartmouth.edu

Phone 603-646-7023

Fax 603-448-5335

2016-12-01

[#DIV28SUPER] NIH HIV Research Priorities

Dear Colleagues,

 

On World AIDS Day, I thought you might be interested in a letter sent by APA and twenty-seven other organizations to HHS Secretary Burwell last February expressing concern about changing research priorities in the NIH Office of AIDS Research (OAR).  In the letter we urged OAR to establish a Working Group under the auspices of the OAR Advisory Council to develop guidelines for the prevention and treatment of HIV in those with substance use disorders.  Unfortunately, ten months later, OAR’s response indicates that is not likely to happen.  As indicated in yesterday’s Washington Post, as well as Dr. Volkow’s blog today, recent CDC figures suggest an increasing need for research in these populations.

 

 

Geoffrey K. Mumford, Ph.D. | Associate Executive Director for Government Relations

Science Directorate
American Psychological Association
750 First Street NE, Washington, DC 20002-4242
Tel: 202.336.6067 |  Fax: 202.336.6063

email: gmumford@apa.org | www.apa.org

   

 

P Most people consider the environment before printing their email.

 

 

 

 

 

[#DIV28SUPER] APA 2017 Convention Abstracts Due TODAY by 5pm EST!

Hello everyone,

A final reminder that convention abstracts are due today by 5pm EST.


Full details are available in the APA Call for Convention Proposals (PDF, 5.8MB).

The link to additional convention information is available here:  http://www.apa.org/convention/proposals.aspx

Warm regards,
Kelly Dunn, Ph.D.
---
Kelly Dunn, Ph.D.
Assistant Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P: 410-550-2254; F: 410-550-0030


[#DIV28SUPER] NYTimes: Hallucinogen Eases Depression in Cancer Patients, Studies Find

http://www.nytimes.com/2016/12/01/health/hallucinogenic-mushrooms-psilocybin-cancer-anxiety-depression.html?smprod=nytcore-iphone&smid=nytcore-iphone-share

Two studies used psilocybin to see if the drug could reduce depression and anxiety in cancer patients. The results were striking.


Sent from my iPhone
_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

2016-11-30

[#DIV28SUPER] APA 2017 Convention Abstracts Due TOMORROW!

Greetings everyone,

As a reminder, the 2017 American Psychological Association Convention will be held from August 3rd – 7th in Washington DC.  As your incoming 2017 Program Chair for Division 28 (Psychopharmacology and Substance Abuse), I ask you to please consider submitting an abstract for the convention.  Abstracts for posters or symposiums are due TOMORROW! 


Full details are available in the APA Call for Convention Proposals (PDF, 5.8MB).

The link to additional convention information is available here:  http://www.apa.org/convention/proposals.aspx

Warm regards,
Kelly Dunn, Ph.D.
---
Kelly Dunn, Ph.D.
Assistant Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P: 410-550-2254; F: 410-550-0030


[#DIV28SUPER] NYTimes: F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients

http://www.nytimes.com/2016/11/29/us/ptsd-mdma-ecstasy.html?smprod=nytcore-iphone&smid=nytcore-iphone-share

The Food and Drug Administration has approved large-scale clinical trials to study MDMA, the illegal party drug better known as Ecstasy, as treatment for PTSD patients.


Sent from my iPhone
_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org